AU2007307157A1 - Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure - Google Patents
Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure Download PDFInfo
- Publication number
- AU2007307157A1 AU2007307157A1 AU2007307157A AU2007307157A AU2007307157A1 AU 2007307157 A1 AU2007307157 A1 AU 2007307157A1 AU 2007307157 A AU2007307157 A AU 2007307157A AU 2007307157 A AU2007307157 A AU 2007307157A AU 2007307157 A1 AU2007307157 A1 AU 2007307157A1
- Authority
- AU
- Australia
- Prior art keywords
- mrs
- intraocular pressure
- eye
- iop
- adenosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85017506P | 2006-10-06 | 2006-10-06 | |
| US60/850,175 | 2006-10-06 | ||
| PCT/US2007/021409 WO2008045330A2 (en) | 2006-10-06 | 2007-10-05 | Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007307157A1 true AU2007307157A1 (en) | 2008-04-17 |
Family
ID=39283379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007307157A Abandoned AU2007307157A1 (en) | 2006-10-06 | 2007-10-05 | Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090258836A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2076267A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010505848A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007307157A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0715318A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2665616A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009003750A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008045330A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013516495A (ja) | 2010-01-11 | 2013-05-13 | イノテック ファーマシューティカルズ コーポレイション | 眼圧を低下させる組合せ、キット、および方法 |
| JP2013523739A (ja) * | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
| SMT201700377T1 (it) | 2012-01-26 | 2017-09-07 | Inotek Pharmaceuticals Corp | Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione |
| NZ630759A (en) | 2013-03-15 | 2017-07-28 | Inotek Pharmaceuticals Corp | Ophthalmic formulations comprising an a1 agonist |
| ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| US10196396B2 (en) | 2016-01-14 | 2019-02-05 | Handok Inc. | Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof |
| ES2676535B1 (es) | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| KR101805400B1 (ko) * | 2017-03-21 | 2017-12-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 |
| CN109666053A (zh) * | 2017-10-16 | 2019-04-23 | 张家口华健致远生物科技有限公司 | 一种a3腺苷受体激动剂及其用途 |
| KR102007640B1 (ko) * | 2017-11-29 | 2019-08-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물 |
| US11395597B2 (en) * | 2018-06-26 | 2022-07-26 | General Electric Company | System and method for evaluating blood flow in a vessel |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4431638B2 (ja) * | 1996-01-29 | 2010-03-17 | アメリカ合衆国 | ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途 |
| EP1096975B1 (en) * | 1998-07-16 | 2005-03-16 | The Trustees Of The University Of Pennsylvania | Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure |
| IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
-
2007
- 2007-10-05 BR BRPI0715318-0A patent/BRPI0715318A2/pt not_active IP Right Cessation
- 2007-10-05 AU AU2007307157A patent/AU2007307157A1/en not_active Abandoned
- 2007-10-05 WO PCT/US2007/021409 patent/WO2008045330A2/en not_active Ceased
- 2007-10-05 EP EP07852549.0A patent/EP2076267A4/en not_active Withdrawn
- 2007-10-05 JP JP2009531464A patent/JP2010505848A/ja active Pending
- 2007-10-05 MX MX2009003750A patent/MX2009003750A/es active IP Right Grant
- 2007-10-05 CA CA002665616A patent/CA2665616A1/en not_active Abandoned
-
2009
- 2009-04-06 US US12/419,062 patent/US20090258836A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0715318A2 (pt) | 2013-07-16 |
| EP2076267A4 (en) | 2013-07-31 |
| US20090258836A1 (en) | 2009-10-15 |
| WO2008045330A2 (en) | 2008-04-17 |
| MX2009003750A (es) | 2009-06-18 |
| JP2010505848A (ja) | 2010-02-25 |
| EP2076267A2 (en) | 2009-07-08 |
| WO2008045330A3 (en) | 2008-06-26 |
| CA2665616A1 (en) | 2008-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090258836A1 (en) | Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure | |
| US6528516B1 (en) | Methods for reducing intraocular pressure using A3 adenosine receptor antagonists | |
| Kent et al. | Vitreous concentration of topically applied brimonidine tartrate 0.2% | |
| Koseki et al. | A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure | |
| Guha et al. | Lysosomal alkalinization, lipid oxidation, and reduced phagosome clearance triggered by activation of the P2X7 receptor | |
| Nuyen et al. | Steroid-induced glaucoma in the pediatric population | |
| Uckermann et al. | The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling | |
| Levy et al. | Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers | |
| Kapin et al. | Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac | |
| Sigurdsson et al. | Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration | |
| Wang et al. | Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species | |
| US12102640B2 (en) | Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration | |
| WO2018009717A1 (en) | Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation | |
| Chien et al. | Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes | |
| Brubaker et al. | Topical forskolin (colforsin) and aqueous flow in humans | |
| JP7816716B2 (ja) | 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法 | |
| Sponsel et al. | Periocular accumulation of timolol and betaxolol in glaucoma patients under long-term therapy | |
| KR20180094879A (ko) | 망막 질환을 치료하기 위한 미라베그론 | |
| Wang et al. | Barrier qualities of the mouse eye to topically applied drugs | |
| US20090054412A1 (en) | Treatment of Sleep Disorders | |
| US10370378B2 (en) | Treatment of sleep disorders | |
| Schoenwald et al. | The ocular pharmacokinetics of ketanserin and its metabolite, ketanserinol, in albino rabbits | |
| Konno et al. | Effect of 2-(6-cyano-1-hexyn-1-yl) adenosine on ocular blood flow in rabbits | |
| Manzoni et al. | P-9-1 Effect of ceftriaxone, gabapentin and lamotrigine on [3H] glutamate uptake in an animal model of amyotrophic lateral sclerosis | |
| WO2006138487A2 (en) | Treatment of ischemia-induced arrhythmias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO-INVENTOR NAME FROM MOR- TIMER, CIVAN M. TO CIVAN, MORTIMER M. |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |